Aigen Investment Management LP Buys Shares of 4,917 DaVita Inc. $DVA

Aigen Investment Management LP bought a new stake in DaVita Inc. (NYSE:DVA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,917 shares of the company’s stock, valued at approximately $559,000.

Other hedge funds also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its holdings in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in DaVita in the second quarter valued at about $43,000. Kestra Advisory Services LLC purchased a new position in DaVita in the fourth quarter valued at about $45,000. iSAM Funds UK Ltd purchased a new position in DaVita in the third quarter valued at about $46,000. Finally, Stance Capital LLC purchased a new position in DaVita in the third quarter valued at about $47,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on DVA. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. TD Cowen increased their target price on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and raised their price objective for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus price target of $199.17.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by company insiders.

DaVita Stock Performance

Shares of NYSE DVA opened at $209.29 on Tuesday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $211.80. The firm’s 50 day moving average price is $177.40 and its 200 day moving average price is $146.89. The firm has a market cap of $13.44 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 0.68 and a beta of 0.91.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter last year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts predict that DaVita Inc. will post 15.07 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.